Alzheon Announces Notice Of Allowance For U.S. Patent For Its Lead Drug Candidate ALZ-801 In Clinical Development For Alzheimer’s Disease
4/15/2014 9:16:43 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that the United States Patent and Trademark Office (US PTO) has issued a notice of allowance for the U.S. Patent Application Number 11/871,639, entitled “Methods, Compounds, Compositions and Vehicles for Delivering 3-Amino-1-Propanesulfonic Acid.” The allowed claims are directed to Alzheon’s lead therapeutic candidate ALZ-801, and protect the ALZ-801 compound, pharmaceutical compositions containing ALZ-801, as well as methods of treating Alzheimer’s disease using ALZ-801. Alzheon is currently advancing ALZ-801 into a confirmatory pivotal Phase 2/3 study in Alzheimer’s disease patients positive for e4 allele of the apolipoprotein E.
Help employers find you! Check out all the jobs and post your resume.
comments powered by